TY - JOUR
T1 - Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors
AU - Zhou, Xiaofei
AU - Richardson, Debra L.
AU - Dowlati, Afshin
AU - Goel, Sanjay
AU - Sahebjam, Solmaz
AU - Strauss, James
AU - Chawla, Sant
AU - Wang, Ding
AU - Mould, Diane R.
AU - Samnotra, Vivek
AU - Faller, Douglas V.
AU - Venkatakrishnan, Karthik
AU - Gupta, Neeraj
N1 - Funding Information:
This work was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding Information:
This work was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The authors thank all the patients who participated in this study and their families, as well as all the investigators and site staff who made the study possible. Editorial support was provided by Ashfield MedComms, an Inizio company, funded by Takeda Pharmaceuticals USA, Inc., and complied with the Good Publication Practice-3 (GPP3) guidelines (Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163:461–464).
Funding Information:
The authors thank all the patients who participated in this study and their families, as well as all the investigators and site staff who made the study possible. Editorial support was provided by Ashfield MedComms, an Inizio company, funded by Takeda Pharmaceuticals USA, Inc., and complied with the Good Publication Practice‐3 (GPP3) guidelines (Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company‐sponsored medical research: GPP3. . 2015;163:461–464). Ann Intern Med
Publisher Copyright:
© 2022 Takeda Pharmaceutical and The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
PY - 2023/3
Y1 - 2023/3
N2 - The purpose of this study was to assess the effect of pevonedistat, a neural precursor cell expressed, developmentally down-regulated protein 8 (NEDD8)-activating enzyme inhibitor, on the heart rate-corrected QT (QTc) interval in cancer patients. Patients were randomized 1:1 to receive pevonedistat 25 or 50 mg/m2 on day 1 and the alternate dose on day 8. Triplicate electrocardiograms were collected at intervals over 0–11 hours and at 24 hours via Holter recorders on days −1 (baseline), 1, and 8. Changes from time-matched baseline values were calculated for QTc by Fridericia (QTcF), PR, and QRS intervals. Serial time-matched blood samples for analysis of pevonedistat plasma pharmacokinetics were collected and a concentration–QTc analysis conducted. Safety was assessed by monitoring vital signs, physical examinations, and clinical laboratory tests. Forty-four patients were included in the QTc analysis. Maximum least square (LS) mean increase from time-matched baseline in QTcF was 3.2 milliseconds at 1 hour postdose for pevonedistat at 25 mg/m2, while the LSs mean change from baseline in QTcF was −1.7 milliseconds 1 hour postdose at 50 mg/m2. The maximum 2-sided 90% upper confidence bound was 6.7 and 2.9 milliseconds for pevonedistat at 25 and 50 mg/m2, respectively. Pevonedistat did not result in clinically relevant effects on heart rate, nor on PR or QRS intervals. Results from pevonedistat concentration–QTc analysis were consistent with these findings. Administration of pevonedistat to cancer patients at a dose of up to 50 mg/m2 showed no evidence of QT prolongation, indicative of the lack of clinically meaningful effects on cardiac repolarization. ClinicalTrials.gov identifier: NCT03330106 (first registered on November 6, 2017).
AB - The purpose of this study was to assess the effect of pevonedistat, a neural precursor cell expressed, developmentally down-regulated protein 8 (NEDD8)-activating enzyme inhibitor, on the heart rate-corrected QT (QTc) interval in cancer patients. Patients were randomized 1:1 to receive pevonedistat 25 or 50 mg/m2 on day 1 and the alternate dose on day 8. Triplicate electrocardiograms were collected at intervals over 0–11 hours and at 24 hours via Holter recorders on days −1 (baseline), 1, and 8. Changes from time-matched baseline values were calculated for QTc by Fridericia (QTcF), PR, and QRS intervals. Serial time-matched blood samples for analysis of pevonedistat plasma pharmacokinetics were collected and a concentration–QTc analysis conducted. Safety was assessed by monitoring vital signs, physical examinations, and clinical laboratory tests. Forty-four patients were included in the QTc analysis. Maximum least square (LS) mean increase from time-matched baseline in QTcF was 3.2 milliseconds at 1 hour postdose for pevonedistat at 25 mg/m2, while the LSs mean change from baseline in QTcF was −1.7 milliseconds 1 hour postdose at 50 mg/m2. The maximum 2-sided 90% upper confidence bound was 6.7 and 2.9 milliseconds for pevonedistat at 25 and 50 mg/m2, respectively. Pevonedistat did not result in clinically relevant effects on heart rate, nor on PR or QRS intervals. Results from pevonedistat concentration–QTc analysis were consistent with these findings. Administration of pevonedistat to cancer patients at a dose of up to 50 mg/m2 showed no evidence of QT prolongation, indicative of the lack of clinically meaningful effects on cardiac repolarization. ClinicalTrials.gov identifier: NCT03330106 (first registered on November 6, 2017).
KW - NEDD8-activating enzyme inhibitor
KW - QTc interval
KW - pevonedistat
KW - pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=85142291953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142291953&partnerID=8YFLogxK
U2 - 10.1002/cpdd.1194
DO - 10.1002/cpdd.1194
M3 - Article
C2 - 36382849
AN - SCOPUS:85142291953
SN - 2160-763X
VL - 12
SP - 257
EP - 266
JO - Clinical Pharmacology in Drug Development
JF - Clinical Pharmacology in Drug Development
IS - 3
ER -